Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Androxal Food Effect PK Study
NCT02146391Phase 1Completed
- Sponsor
- Repros Therapeutics Inc.
- Start
- Jun 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of enclomiphene in secondary hypogonadism (HH), sponsored by Repros Therapeutics Inc. Primary endpoint: Maximum Plasma Concentration at 24 hours. Started Jun 2014; status: completed.
02
Drugs
enclomiphene
03
Conditions
secondary hypogonadism (HH)
Beyond the preview
Go deeper on NCT02146391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02146391.